Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Gac. méd. Méx ; 141(5): 363-366, sep.-oct. 2005. tab
Artigo em Espanhol | LILACS | ID: lil-632091

RESUMO

Objetivo: Comparar la eficacia y seguridad de las suspensiones oftálmicas de acetato de prednisolona al 1% y de rimexolona al 1%, en el tratamiento de la uveítis anterior aguda (UAA) en pacientes HLA B27+. Material y métodos: Se seleccionaron al azar 68 pacientes con UAA HLA -B27+ para tratamiento con acetato de prednisolona al 1% o rimexolona al 1%. En todos los pacientes la inflamación en cámara anterior era leve a moderada. La presión intraocular (PIO) y el grado de inflamación fueron evaluados semanalmentre durante seis semanas. Fue un estudio clínico prospectivo, aleatorio y doble ciego. Resultados: Al cuantificar las células en cámara anterior no se encontraron diferencias estadísticamente significativas entre uno y otro grupos. En el grupo de rimexolona el flare disminuyó desde la primera semana. En los grupos la presión intraocular se elevó con respecto a la basal desde la primera semana, la variación fue más significativa en el grupo de rimexolona. La PIO final fue menor en el grupo de rimexolona, siendo esta diferencia estadísticamente significativa . Conclusión: Para el tratamiento de la UAA HLA -B27+, leve a moderada, la rimexolona al 1% y la prednisolona al 1% tiene una eficiencia similar. En este estudio las variaciones de presión intraocular en los dos grupos no fueron clínicamente significativas.


Purpose: To compare the efficacy and safety of prednisolone acetate 1 % vs. rimexolone 1 % ophthalmic suspension in the treatment of acute anterior uveitis (AAU) in HLA-B27+ patients. Methods: Sixty-eight AAU HLA-B27+ patients were randomly selected for treatment with prednisolone acetate 1% or Rimexolone 1%. All patients showed mild to moderate anterior chamber inflammation. This was a prospective, randomized, double blind, clinical trial. Results: There was no statistically significant difference between both groups when anterior chamber cells were measured. In the rimexolone group, flare diminished since the first week. In both groups the intraocular pressure (IOP) raised since the first week; the increase washighly significant in the rimexolone group. Final intraocular pressure was higher in the prednisolone group. Conclusion: Rimexolone 1 % is as effective as prednisolone acetate 1% in the treatment of mild to moderate AAU HLA B27+. IOP increased in both groups, but this variation was not clinically significant.


Assuntos
Adulto , Feminino , Humanos , Masculino , Anti-Inflamatórios/uso terapêutico , Prednisolona/uso terapêutico , Pregnadienos/uso terapêutico , Uveíte/tratamento farmacológico , Doença Aguda , Método Duplo-Cego , /sangue , Estudos Longitudinais , Estudos Prospectivos , Uveíte/sangue
2.
Journal of the Korean Ophthalmological Society ; : 2336-2341, 2003.
Artigo em Coreano | WPRIM | ID: wpr-16663

RESUMO

PURPOSE: We compared therapeutic efficacy and steroid-induced IOP elevation of 1% rimexolone with that of 0.1% fluorometholone. METHODS: Of all LASIK treated eyes from March of 2001 to December of 2002 in Sungae General Hospital, 46 eyes were treated with 1% rimexolone and 46 eyes were treated with 0.1% fluorometholone. And we measured the degree of myopic regression (1 day, 1 month, 3 month) and intraocular pressure (1 month). RESULTS: Statistically signicant difference in therapeutic efficacy of myopic regression, and no statistically signicant difference in IOP were found. The therapeutic efficacy of 1% rimexolone was higher. CONCLUSIONS: We concluded that application of 1% rimexolone was more useful in myopic regression following LASIK rather than that of 0.1% fluorometholone.


Assuntos
Fluormetolona , Hospitais Gerais , Pressão Intraocular , Ceratomileuse Assistida por Excimer Laser In Situ
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA